BELLEVUE, Wash. - (Business Wire) PhysioSonics, Inc., an innovator of noninvasive neurologic monitors, announced today the closure of the second tranche of Series A financing for $ 2.0 Million from a strategic investor. The first tranche of Series A closed for $4.0 Million in 2008. This follow-on investment of $2.0 Million by another strategic partner will bring the total Series A funds raised to $6.0 Million.
The company will use these funds for commercialization of their first product "We are very excited with the continued validation of our product development as more neurosurgeons, anesthesiologists and cardiologists view our technology," says Brad Harlow, President& CEO of PhysioSonics.
About PhysioSonics, Incorporated
PhysioSonics is developing and patented a number of new technologies including an ultrasound-based transcranial Doppler (TCD) monitor neuromonitor. Its founders include Robert Frederickson Ph.D., Michel Kliot M.D., Pierre Mourad, Ph.D., and Jeffrey Jarvik, M.D., MPH developed the technology at the University of Washington.
Formerly known as Allez Physionix, PhysioSonics, is a privately held.
PhysioSonics
Brad Harlow, 425-952-4411 x301
President & CEO
bradh@physiosonics.com
